CHEK2 and breast carcinoma: Based on our analyses, breast cancers of p.I157T and c.1100delC CHEK2 mutation carriers differ in disease severity as seen especially in differences in tumor grade and patient survival, as well as in intrinsic biological features as seen in differences in histological type and gene expression profiles.